Boston Scientific's Strategic Acquisition of Penumbra
January 15, 2026 - 22:28
In a significant move, Boston Scientific has announced its intention to acquire Penumbra in a deal valued at $14.5 billion. This transaction, which combines cash and stock, sets Penumbra's share price at $374. The acquisition is poised to enhance Boston Scientific's existing vascular and neurovascular portfolios, enabling the company to offer an expanded range of treatments for critical cardiovascular conditions.
With this acquisition, Boston Scientific aims to strengthen its capabilities in addressing serious health issues such as pulmonary embolism, stroke, and deep vein thrombosis. The integration of Penumbra's innovative technologies and products will not only broaden the company's therapeutic options but also reinforce its position as a leader in the medical device industry.
This strategic move underscores Boston Scientific's commitment to advancing patient care and improving outcomes in the vascular and neurovascular spaces, ultimately benefiting healthcare providers and patients alike.
MORE NEWS
May 31, 2026 - 01:30
Major Portland companies collaborate to eliminate single-use cupsThree Portland-area companies have joined forces to tackle the waste problem at live events. McMenamins, Bold Reuse, and Straightaway Cocktails have launched a new reusable cup program at Edgefield...
May 30, 2026 - 20:39
Community is Better and StrongerMarch 24, 2023 is a date the people of Rolling Fork and Sharkey County will never forget. That evening, a powerful EF-4 tornado tore through the heart of the community, leaving behind a level of...
May 30, 2026 - 07:11
34,000 Small Businesses Said AI Is Working. The Data Says OtherwiseA new study from QuickBooks tracking 34,000 small businesses has revealed a surprising disconnect. While a majority of owners say artificial intelligence is helping their operations, the hard data...
May 29, 2026 - 19:13
FDA sees potential in new AI software for monitoring heart failure patientsThe U.S. Food and Drug Administration has indicated it sees promise in a new artificial intelligence platform designed to monitor heart failure patients outside of the hospital. The software-only...